You are here
Monday, March 21, 2011
World TB Day, March 24, 2011
Statement of Christine F. Sizemore, Ph.D., and Anthony S. Fauci, M.D., National Institute of Allergy and Infectious Diseases, National Institutes of Health.
The theme of World TB Day 2011 — "On the move against TB: Transforming the fight towards elimination"— reflects renewed momentum to approach the global problem of tuberculosis with greater intensity and seriousness of purpose. This growing interest is broad-based, emerging from leaders in public health to laboratory scientists, from physicians to activists.
Today, about one-third of the world's population is infected with Mycobacterium tuberculosis (Mtb), the bacterium that causes TB. Most people have no symptoms because the bacterium is inactive, or latent, but individuals with symptoms of active TB disease can infect others. According to World Health Organization (WHO) estimates, in 2009 more than 14 million people had active TB, leading to 1.7 million deaths, or 4,600 deaths each day. Among people infected with the bacteria, those who have certain other conditions, such as HIV/AIDS and diabetes, are more likely to develop active TB and to die from it. Because of this deadly synergy, TB has become the leading cause of death among people with HIV/AIDS.
Although TB control programs have led to a decline in cases worldwide, the emergence and spread of drug-resistant strains of Mtb challenge the way we currently approach TB diagnosis and treatment. Extensively drug-resistant TB, while relatively rare, has been confirmed in 58 countries, including the United States, and likely is present in many more. It has become necessary not just to identify the infection but also to determine the proper therapy for patients at the earliest stages of disease.
Recent developments have created confidence that TB control strategies can be improved to stay abreast of the changing nature of the pandemic. For the first time in decades, a robust pipeline of candidate TB drugs, vaccines, diagnostics, and treatment and prevention strategies are being evaluated in clinical trials. WHO recently endorsed a diagnostic test that enables health care providers to identify drug-resistant TB directly from patient specimens within about two hours rather than waiting months for a conclusive diagnosis. Drugs are being developed that, when combined in novel ways, may significantly improve the way we treat patients with TB. Vaccines are being developed that may one day prevent the disease, even in persons who are already infected with Mtb.
While such advances are crucial to improve patient care, a true transformation in the fight against TB can occur only if we simultaneously deepen our understanding of TB as a disease. For example, a noninvasive means to determine whether an individual is containing the infection or progressing to active disease — what's called a biomarker — would be of enormous benefit to patient care and for conducting clinical trials of therapies and vaccines. Additionally, although 90 percent of people infected with Mtb never develop active disease, latent TB infection remains largely mysterious. Increasing our knowledge in these and other fundamental areas is a research priority for the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. New and improved laboratory and clinical tools, as well as collaborations between all disciplines of biomedical research, are now being engaged to characterize the interactions at play during the course of Mtb infection and TB disease. The extraordinary complexity of the TB disease process makes it well-suited to being examined as an integrated whole, an approach successful in yielding insights into other complicated diseases.
Together with our global partners, we at NIAID are encouraged by recent progress in TB research. By fostering a comprehensive TB research agenda and innovation at all levels, and by addressing TB with research tools appropriate to the health care challenges we face in the 21st century, we can continue to make great strides. World TB Day reminds us that although TB has afflicted mankind for millennia, we have yet to understand it in modern terms. We must use cutting-edge technologies to ask and answer fundamental questions that have never been adequately addressed. Only in this way will we transform our fight against TB towards elimination of this ancient scourge.
For more information about TB, visit NIAID’s Tuberculosis Web portal (http://www.niaid.nih.gov/topics/tuberculosis/Pages/Default.aspx) and the HHS TB Web site (http://www.hhs.gov/tb/ ).
Anthony S. Fauci, M.D., is director of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. Christine F. Sizemore, Ph.D., is chief of the Tuberculosis and Other Mycobacterial Diseases Section in the NIAID Division of Microbiology and Infectious Diseases.
NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®